SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC  20549

                                 ________________

                                     FORM 8-K

                                  CURRENT REPORT
                        PURSUANT TO SECTION 13 OR 15(D) OF
                        THE SECURITIES EXCHANGE ACT OF 1934


        Date of report (Date of earliest event reported)  June 10, 1999


                                       SCIOS INC.
                   (Exact Name of Registrant as Specified in Charter)



         Delaware                   0-11749                   95-3701481
(State of Other Jurisdiction      (Commission               (IRS Employer
        of Incorporation)         File Number)            Identification No.)



            2450 Bayshore Parkway, Mountain View, California  94043
                     (Address of Principal Executive Offices)



       Registrant's telephone number, including area code  (650) 966-1550











Item 5.  Other Events

         On June 9, 1999, Scios Inc. announced that the May 11, 1998 commercial
alliance with Bayer Corporation regarding Natrecor(R) (nesiritide) was
terminated.


Exhibits.

         99.1     Press Release dated June 9, 1999



         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this amendment to be signed on its behalf of the
undersigned, thereunto duly authorized.

                                                     SCIOS INC.


Date:  June 10, 1999                          By:
                                                       David S. Gryska
                                                       Chief Financial Officer



                                INDEX TO EXHIBITS

                                    SCIOS INC.

                     Report on Form 8-K dated June 10, 1999




Exhibit     Description                           Method of Filing

99.1        Press Release dated June 9, 1999      Filed electronically herewith


                                                             Exhibit 99.1










   SCIOS AND BAYER DISSOLVE COMMERCIAL ALLIANCE REGARDING NATRECOR(R) IN
                   ACUTE CONGESTIVE HEART FAILURE

- -Scios designing new clinical trial while reviewing new partner opportunities-


MOUNTAIN VIEW, Calif. - June 9, 1999 - Scios Inc. (NASDAQ: SCIO) today announced
that  the  commercial  alliance  with  Bayer  Corporation,  formed  in May  1998
regarding  Natrecor(R)  (nesiritide) in acute congestive heart failure, has been
dissolved.  Scios recently received notice from the Food and Drug Administration
(FDA) that Natrecor  would need to  successfully  complete  additional  clinical
study to gain approval.

"Bayer decided to reassess the basis of its continued commercial alliance with
Scios regarding Natrecor after the FDA non-approvable letter on the Natrecor
new drug application," said Richard B. Brewer, President and CEO of Scios Inc.
"Agreement could not be reached on a new commercial alliance."

With the  dissolution  of the alliance  with Bayer  Corporation,  all rights and
responsibilities for Natrecor development and commercialization revert to Scios.
As a result the company is reviewing new partner  opportunities.  The company is
now directing its full  attention to designing an additional  clinical  trial to
meet the FDA's  concerns  expressed in the April,  1999 Natrecor  non-approvable
letter.  Scios is  collaborating  with outside  experts in the congestive  heart
failure  community in the design of the next clinical study. In addition,  Scios
will work in close  collaboration  with the FDA.  The full  details of the trial
will probably not be available until  mid-summer  (i.e.  trial  enrollment size,
length of study, and cost).

Scios Inc.
Scios is a  biopharmaceutical  company  engaged in the  discovery,  development,
manufacture  and  commercialization  of  novel  human  therapeutics.  Scios  has
research and development  collaborations  with  Wyeth-Ayerst  Laboratories,  the
pharmaceutical   division  of  American   Home   Products   Corporation,   Kaken
Pharmaceutical  Co.,  Ltd.,  Eli Lilly and  Company,  The DuPont Pharmaceuticals
Company and Novo Nordisk A/S of Denmark.  Scios' commercial  operations division
successfully markets six psychiatric products.  Additional  information on Scios
is  available  at its web site  located  at  http://www.sciosinc.com  and in the
Company's various fillings with the Securities and Exchange Commission.

The  statements  in this  press  release  that  are  not  historical  facts  are
forward-looking statements that involve risks and uncertainties, and may include
references to the continued  development and  commercialization of Natrecor,  as
well as other risks  detailed  from time to time in the  reports  filed by Scios
with the SEC,  including  annual reports on Form 10K for the year ended December
31, 1998 and subsequent reports on Form 10Q.
                                                                 # # #